Matteo Vittori
Research Subjects
Matteo Vittori has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Riccardo Bertolo
University of Verona, AOUI Verona, Verona, Italy
6 shared publications - Valerio Iacovelli
Urology Unit, Department of Surgery, University of Rome Tor Vergata, 00133 Rome, Italy
6 shared publications - Pierluigi Bove
Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy
5 shared publications - Chiara Cipriani
Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
3 shared publications Filomena Petta
Urology Unit, San Carlo di Nancy General Hospital - GVM Care and Research, Rome; Minimally Invasive and Robotic Urology Unit, Tor Vergata University of Rome
3 shared publications- Giovanni Gambaro
Division of Nephrology, Department of Medicine, University of Verona , Verona
3 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4311
Molecular Evaluation of RNA-Based Immune Checkpoint Profiling in Clear Cell Renal Cell Carcinoma
Background: Clear cell renal cell carcinoma is considered an immunologically “hot” tumor, with an abundance of tumor-infiltrating immune cells. This feature has a strong effect on therapeutic outcomes, especially in immune therapies. Within this context, immune checkpoint expression plays a central role in RCC immunotherapy, establishing new standards of care for patients with advanced RCC. However, most patients do not derive the maximum benefit from immune checkpoint inhibitors and may experience severe adverse effects. This may highlight the need to better understand the complexity of immunosuppressive mechanisms within the tumor microenvironment, which involves a variety of molecules. As such, this study aims to characterize the immune checkpoint status by investigating the co-expression (RNASeq) of the main checkpoints in a cohort of 16 ccRCC. Results: In the investigated cohort, the evaluation of immune checkpoint molecules revealed the complexity of immune regulatory mechanisms within the tumor microenvironment. The marked heterogeneity in the expression of eight major immune checkpoint actors, namely, PD1, PDL1, CTLA4, PDL2, VISTA, TIM3, TIGIT, and LAG3, is matched by multiple co-expressed immune checkpoint molecules, making the immune checkpoint burden score. Specifically, immune-cold tumors displayed the highest degree of co-expression, together with high levels of PDL2 and VISTA. Furthermore, the expression of immune checkpoints, both individually and collectively, was positively associated with intratumoral immune cytolytic activity, highlighting the coexistence of immune activation and immune suppression as tightly interconnected processes. Conclusions: The data presented here supports the concept that a ccRCC microenvironment may be driven by multiple modulatory mechanisms that allow immune escape to happen. Revealing the coordination of immune checkpoint molecules and the compensatory upregulation mechanisms may support future studies exploring multi-target immunotherapeutic strategies.
- 2 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4311
Open AccessMolecular Evaluation of RNA-Based Immune Checkpoint Profiling in Clear Cell Renal Cell Carcinoma
Background: Clear cell renal cell carcinoma is considered an immunologically “hot” tumor, with an abundance of tumor-infiltrating immune cells. This feature has a strong effect on therapeutic outcomes, especially in immune therapies. Within this context, immune checkpoint expression plays a central role in RCC immunotherapy, establishing new standards of care for patients with advanced RCC. However, most patients do not derive the maximum benefit from immune checkpoint inhibitors and may experience severe adverse effects. This may highlight the need to better understand the complexity of immunosuppressive mechanisms within the tumor microenvironment, which involves a variety of molecules. As such, this study aims to characterize the immune checkpoint status by investigating the co-expression (RNASeq) of the main checkpoints in a cohort of 16 ccRCC. Results: In the investigated cohort, the evaluation of immune checkpoint molecules revealed the complexity of immune regulatory mechanisms within the tumor microenvironment. The marked heterogeneity in the expression of eight major immune checkpoint actors, namely, PD1, PDL1, CTLA4, PDL2, VISTA, TIM3, TIGIT, and LAG3, is matched by multiple co-expressed immune checkpoint molecules, making the immune checkpoint burden score. Specifically, immune-cold tumors displayed the highest degree of co-expression, together with high levels of PDL2 and VISTA. Furthermore, the expression of immune checkpoints, both individually and collectively, was positively associated with intratumoral immune cytolytic activity, highlighting the coexistence of immune activation and immune suppression as tightly interconnected processes. Conclusions: The data presented here supports the concept that a ccRCC microenvironment may be driven by multiple modulatory mechanisms that allow immune escape to happen. Revealing the coordination of immune checkpoint molecules and the compensatory upregulation mechanisms may support future studies exploring multi-target immunotherapeutic strategies.
- Open Access
- 30 September 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (3) , 14332
Sexual safety and efficacy of a pollen extract and teupolioside-based supplement in men with benign prostatic hyperplasia: a prospective observational study
Background: Benign prostatic hyperplasia (BPH) is a common age-related condition that often results in lower urinary tract symptoms (LUTS), reduced quality of life, and sexual dysfunction. Conventional pharmacotherapies, while effective, are frequently associated with adverse effects on sexual and ejaculatory function. This study evaluated the sexual safety and clinical efficacy of a dietary supplement containing pollen extract and teupolioside, in men with BPH. Methods: In this prospective, single-arm observational study, 25 men with moderate LUTS due to BPH received daily pollen extract and teupolioside supplementation for 90 days. The primary endpoints were sexual function (International Index of Erectile Function, IIEF-5), ejaculatory function (Male Sexual Health Questionnaire–Ejaculatory Dysfunction, MSHQ-EjD), quality of life (IPSS-QoL), and patient global impression of improvement (PGI-I). Secondary endpoints included changes in urinary flow (Qmax) and LUTS severity (International Prostate Symptom Score, IPSS). Assessments were conducted at baseline, 1 month, and 3 months. Results: Sexual and ejaculatory functions remained stable over the treatment period, with no statistically significant deterioration observed. QoL improved significantly by the 3-month mark (IPSS-QoL median score reduced from 3 to 2; p<0.008), and PGI-I scores reflected high patient satisfaction (median 2, IQR 1). Qmax significantly increased from 12.4 mL/s at baseline to 15.5 mL/s at 3 months (p<0.001), and IPSS scores significantly declined from 11 to 8 (p<0.008), indicating improved urinary function. Conclusions: The pollen extract and teupolioside supplementation was well tolerated and associated with improved QoL and urinary outcomes, without compromising sexual or ejaculatory function. These findings support its potential as a non-pharmacologic adjunct in the management of BPH, particularly in patients concerned about sexual side effects. Further randomized controlled studies are warranted to confirm these results.
- 30 September 2025
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 97 (3) , 14332
Open AccessSexual safety and efficacy of a pollen extract and teupolioside-based supplement in men with benign prostatic hyperplasia: a prospective observational study
Background: Benign prostatic hyperplasia (BPH) is a common age-related condition that often results in lower urinary tract symptoms (LUTS), reduced quality of life, and sexual dysfunction. Conventional pharmacotherapies, while effective, are frequently associated with adverse effects on sexual and ejaculatory function. This study evaluated the sexual safety and clinical efficacy of a dietary supplement containing pollen extract and teupolioside, in men with BPH. Methods: In this prospective, single-arm observational study, 25 men with moderate LUTS due to BPH received daily pollen extract and teupolioside supplementation for 90 days. The primary endpoints were sexual function (International Index of Erectile Function, IIEF-5), ejaculatory function (Male Sexual Health Questionnaire–Ejaculatory Dysfunction, MSHQ-EjD), quality of life (IPSS-QoL), and patient global impression of improvement (PGI-I). Secondary endpoints included changes in urinary flow (Qmax) and LUTS severity (International Prostate Symptom Score, IPSS). Assessments were conducted at baseline, 1 month, and 3 months. Results: Sexual and ejaculatory functions remained stable over the treatment period, with no statistically significant deterioration observed. QoL improved significantly by the 3-month mark (IPSS-QoL median score reduced from 3 to 2; p<0.008), and PGI-I scores reflected high patient satisfaction (median 2, IQR 1). Qmax significantly increased from 12.4 mL/s at baseline to 15.5 mL/s at 3 months (p<0.001), and IPSS scores significantly declined from 11 to 8 (p<0.008), indicating improved urinary function. Conclusions: The pollen extract and teupolioside supplementation was well tolerated and associated with improved QoL and urinary outcomes, without compromising sexual or ejaculatory function. These findings support its potential as a non-pharmacologic adjunct in the management of BPH, particularly in patients concerned about sexual side effects. Further randomized controlled studies are warranted to confirm these results.
- Open Access
- 27 August 2025
- Published by OAE Publishing Inc. in Mini-invasive Surgery
- Vol. 9
Sutureless off-clamp robot-assisted partial nephrectomy: a single-surgeon case series with insights into technique and complications
Aim: Previous literature has evaluated the feasibility and safety of robot-assisted partial nephrectomy (RAPN) performed entirely sutureless and off-clamp. The aim of the present study was to report a series of consecutive, unselected patients with renal masses of intermediate complexity who underwent sutureless off-clamp robot-assisted partial nephrectomy (sl-oc RAPN) by a single surgeon, focusing on surgical strategies, technique, and safety. Methods: A retrospective analysis was conducted on 29 patients between January 2022 and September 2024. Preoperative clinical characteristics, intraoperative data, and postoperative outcomes were examined, with particular attention to adverse events classified according to the Clavien-Dindo system. Additionally, hemoglobin, serum creatinine, and estimated glomerular filtration rate (eGFR) were analyzed at discharge and at three months postoperatively. Results: The median patient age was 60 years. All tumors were classified as T1a or T1b according to the tumor, node, metastasis (TNM) system. The median tumor diameter was 30 mm (range: 28-45), and the median PADUA score was 8 (range: 7-8). The median operative time (OT) was 135 min (range: 110/160), and the median estimated blood loss (EBL) was 100 mL (range: 50-100). Serum creatinine and eGFR at discharge and three months postoperatively showed no statistically significant changes (P > 0.05). Three patients (10%) experienced Clavien-Dindo ≥ 3 complications: two developed urine leakage requiring ureteral stent placement, and one experienced postoperative bleeding requiring blood transfusions. Conclusion: Although limited by a small sample size and the absence of a control group, and with urinary fistula as a potential limitation of the technique, sl-oc RAPN appears effective for treating intermediate-complexity renal tumors. It maintains oncological outcomes, minimizes complications, and preserves renal function.
- 27 August 2025
- Published by OAE Publishing Inc. in Mini-invasive Surgery
- Vol. 9
Open AccessSutureless off-clamp robot-assisted partial nephrectomy: a single-surgeon case series with insights into technique and complications
Aim: Previous literature has evaluated the feasibility and safety of robot-assisted partial nephrectomy (RAPN) performed entirely sutureless and off-clamp. The aim of the present study was to report a series of consecutive, unselected patients with renal masses of intermediate complexity who underwent sutureless off-clamp robot-assisted partial nephrectomy (sl-oc RAPN) by a single surgeon, focusing on surgical strategies, technique, and safety. Methods: A retrospective analysis was conducted on 29 patients between January 2022 and September 2024. Preoperative clinical characteristics, intraoperative data, and postoperative outcomes were examined, with particular attention to adverse events classified according to the Clavien-Dindo system. Additionally, hemoglobin, serum creatinine, and estimated glomerular filtration rate (eGFR) were analyzed at discharge and at three months postoperatively. Results: The median patient age was 60 years. All tumors were classified as T1a or T1b according to the tumor, node, metastasis (TNM) system. The median tumor diameter was 30 mm (range: 28-45), and the median PADUA score was 8 (range: 7-8). The median operative time (OT) was 135 min (range: 110/160), and the median estimated blood loss (EBL) was 100 mL (range: 50-100). Serum creatinine and eGFR at discharge and three months postoperatively showed no statistically significant changes (P > 0.05). Three patients (10%) experienced Clavien-Dindo ≥ 3 complications: two developed urine leakage requiring ureteral stent placement, and one experienced postoperative bleeding requiring blood transfusions. Conclusion: Although limited by a small sample size and the absence of a control group, and with urinary fistula as a potential limitation of the technique, sl-oc RAPN appears effective for treating intermediate-complexity renal tumors. It maintains oncological outcomes, minimizes complications, and preserves renal function.
- Open Access
- 20 February 2025
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 24 (02) , 128-137
Diuretic Renography in a Sitting Position with F + 10(sp) Method for Diagnostic Management of Primary Megaureter in Adults
Objective Primary megaureter is a disease defined as the dilatation of the ureter caused by a congenital abnormality of the lower ureteral tract. Adult patients with primary megaureters typically present with no symptoms, making conservative management the preferred treatment. However, if an obstruction is present, we recommend ureteral reimplantation. The major diagnostic challenge is to distinguish which patients need surgical intervention. Ultrasound, computed tomography, and magnetic resonance imaging urogram findings of obstruction may be misleading because they are based on morphological aspects, and persistence of contrast in the upper urinary tract is not specific for obstruction. Renal scintigraphy is the key test for choosing surgical or conservative treatment; historically, the criterion for surgical treatment is the decrease of split renal function (SRF) less than 40%. Unfortunately, SRF might be only an indirect finding of obstruction; otherwise, the 20-minute/peak ratio may offer urologists an earlier, direct, and reliable index of urine outflow in monitoring ureteral flow. This study suggests that the F + 10(sitting position) test, which measures diuretic renography (DR) in a sitting position, is a new and useful way to find out how well primary megaureters are working for diagnosing and treating them. It focuses on the 20-minute/peak ratio that can be found when gravity is favorable. Methods Twenty-eight adult patients (15 males, 13 females) affected by primary megaureter were retrospectively enrolled. Twenty-six patients had unilateral megaureter, and 2 patients had bilateral megaureter, for a total of 30 megaureters radiologically confirmed (16 left, 14 right). In total, we performed twenty-eight 99mTc-mercaptoacetyltriglycine DR in a sitting position using the F + 10 (sitting position) method. In our series, 17 patients received conservative treatment, and 11 patients underwent ureteral reimplantation. Results Based on the 20-minute/peak ratio values, 17 out of 30 megaureters were diagnosed as obstructed. A discordance between SRF and 20-minute/peak ratio findings has been seen. No side effects were seen. Conclusion A decrease in SRF is an indirect and late index of obstruction. Twenty-minute/peak ratio measured by DR in sitting position may improve the sensitivity and accuracy of the test for diagnosis of obstructive megaureters.
- 20 February 2025
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 24 (02) , 128-137
Open AccessDiuretic Renography in a Sitting Position with F + 10(sp) Method for Diagnostic Management of Primary Megaureter in Adults
Objective Primary megaureter is a disease defined as the dilatation of the ureter caused by a congenital abnormality of the lower ureteral tract. Adult patients with primary megaureters typically present with no symptoms, making conservative management the preferred treatment. However, if an obstruction is present, we recommend ureteral reimplantation. The major diagnostic challenge is to distinguish which patients need surgical intervention. Ultrasound, computed tomography, and magnetic resonance imaging urogram findings of obstruction may be misleading because they are based on morphological aspects, and persistence of contrast in the upper urinary tract is not specific for obstruction. Renal scintigraphy is the key test for choosing surgical or conservative treatment; historically, the criterion for surgical treatment is the decrease of split renal function (SRF) less than 40%. Unfortunately, SRF might be only an indirect finding of obstruction; otherwise, the 20-minute/peak ratio may offer urologists an earlier, direct, and reliable index of urine outflow in monitoring ureteral flow. This study suggests that the F + 10(sitting position) test, which measures diuretic renography (DR) in a sitting position, is a new and useful way to find out how well primary megaureters are working for diagnosing and treating them. It focuses on the 20-minute/peak ratio that can be found when gravity is favorable. Methods Twenty-eight adult patients (15 males, 13 females) affected by primary megaureter were retrospectively enrolled. Twenty-six patients had unilateral megaureter, and 2 patients had bilateral megaureter, for a total of 30 megaureters radiologically confirmed (16 left, 14 right). In total, we performed twenty-eight 99mTc-mercaptoacetyltriglycine DR in a sitting position using the F + 10 (sitting position) method. In our series, 17 patients received conservative treatment, and 11 patients underwent ureteral reimplantation. Results Based on the 20-minute/peak ratio values, 17 out of 30 megaureters were diagnosed as obstructed. A discordance between SRF and 20-minute/peak ratio findings has been seen. No side effects were seen. Conclusion A decrease in SRF is an indirect and late index of obstruction. Twenty-minute/peak ratio measured by DR in sitting position may improve the sensitivity and accuracy of the test for diagnosis of obstructive megaureters.
- 29 August 2024
- Published by SAGE Publications in Urologia Journal
- Vol. 91 (4) , 681-686
Oral supplementation with probiotics, potassium citrate, and magnesium in reducing crystalluria in stone formers: A phase II study
Introduction: Crystalluria is an important indicator of renal stone recurrence. Mechanisms underlying urinary stone formation are still not fully understood and raising interests has been giving to intestinal commensal bacteria for their contribute in maintaining urinary solutes equilibrium. The aim of our phase II study was to examine the administration of potassium citrate, magnesium and probiotics in order to reduce crystalluria. Materials and Methods: Since May 2021, we enrolled 23 patients candidates for ureterorenolithotripsy for calcium oxalate kidney stones with crystalluria and a normal metabolic profile. The analysis was validated by the Institution’s Ethical Committee (no. approval STS CE Lazio 1/N-823). At discharge, patients were provided with daily food supplementation for 20 days of 1 billion Lactobacillus paracasei LPC09, 1 billion Lactobacillus plantarum LP01, 1 billion Bifidobacterium breve BR03, potassium (520 mg), citrate (1400 mg), and magnesium (80 mg). Crystalluria was re-assessed at 1, 3, 6, and 12-months follow-up by polarized light microscopy. Results: After one month from the oral supplementation, no patient reported crystalluria; at 3 months, among the 20 participants available for re-evaluation, still no patient reported crystalluria. Instead, crystalluria was reported in three patients (15%) at 6 months, and in five patients (25%) at 12 months follow-up. Conclusions: The oral supplementation with Lactobacillus spp. and Bifidobacterium spp. was found able to reduce the prevalence of crystalluria in a cohort of patients with diagnosis of calcium oxalate kidney stones with crystalluria candidate to ureterorenolithotripsy.
- 29 August 2024
- Published by SAGE Publications in Urologia Journal
- Vol. 91 (4) , 681-686
Oral supplementation with probiotics, potassium citrate, and magnesium in reducing crystalluria in stone formers: A phase II study
Introduction: Crystalluria is an important indicator of renal stone recurrence. Mechanisms underlying urinary stone formation are still not fully understood and raising interests has been giving to intestinal commensal bacteria for their contribute in maintaining urinary solutes equilibrium. The aim of our phase II study was to examine the administration of potassium citrate, magnesium and probiotics in order to reduce crystalluria. Materials and Methods: Since May 2021, we enrolled 23 patients candidates for ureterorenolithotripsy for calcium oxalate kidney stones with crystalluria and a normal metabolic profile. The analysis was validated by the Institution’s Ethical Committee (no. approval STS CE Lazio 1/N-823). At discharge, patients were provided with daily food supplementation for 20 days of 1 billion Lactobacillus paracasei LPC09, 1 billion Lactobacillus plantarum LP01, 1 billion Bifidobacterium breve BR03, potassium (520 mg), citrate (1400 mg), and magnesium (80 mg). Crystalluria was re-assessed at 1, 3, 6, and 12-months follow-up by polarized light microscopy. Results: After one month from the oral supplementation, no patient reported crystalluria; at 3 months, among the 20 participants available for re-evaluation, still no patient reported crystalluria. Instead, crystalluria was reported in three patients (15%) at 6 months, and in five patients (25%) at 12 months follow-up. Conclusions: The oral supplementation with Lactobacillus spp. and Bifidobacterium spp. was found able to reduce the prevalence of crystalluria in a cohort of patients with diagnosis of calcium oxalate kidney stones with crystalluria candidate to ureterorenolithotripsy.
- Open Access
Transperineal Laser Ablation for Focal Therapy of Localized Prostate Cancer: 12-Month Follow-up Outcomes from a Single Prospective Cohort Study
Introduction and objectives: To evaluate the oncological and functional outcomes of transperineal laser ablation (TPLA) as the focal therapy for localized prostate cancer (PCa) after a 12-month follow-up. Materials and methods: Patients with low- and intermediate-risk localized PCa were prospectively treated with focal TPLA between July 2021 and December 2022. The inclusion criteria were the following: clinical stage < T2b; PSA < 20 ng/mL; International Society of Urological Pathology (ISUP) grade ≤ 2; MRI-fusion biopsy-confirmed lesion classified as PI-RADS v2.1 ≥ 3. Intra-, peri-, and post-operative data were collected. Variables including age, PSA, prostate volume (PVol), Charlson’s Comorbidity Index (CCI), International Prostate Symptom Score (IPSS) with QoL score, International Index of Erectile Function (IIEF-5), International Consultation on Incontinence Questionnaire—Short Form (ICIQ-SF), and Male Sexual Health Questionnaire—Ejaculatory Dysfunction Short Form (MSHQ-EjD) were collected at baseline and at 3, 6 and 12 months after TPLA. Post-operative mpMRI was performed at 3 and 12 months. Finally, all patients underwent prostatic re-biopsy under fusion guidance at 12 months. The success of this technique was defined as no recurrence in the target treated lesion at the 12-month follow up. Results: Twenty-four patients underwent focal TPLA. Baseline features were age [median 67 years (IQR 12)], PSA [5.7 ng/mL (3.9)], PVol [49 mL (27)], CCI [0 (0)], IPSS [11 (9)], IPSS-QoL [2 (2)], IIEF-5 [21 (6)], ICIQ-SF [0 (7)], MSHQ-EjD ejaculation domain [14 (4)] and bother score [0 (2)]. Median operative time was 34 min (IQR 12). Median visual analogue scale (VAS) 6 h after TPLA was 0 (IQR 1). The post-operative course was regular for all patients, who were discharged on the second post-operative day and underwent catheter removal on the seventh post-operative day. No patient had incontinence at catheter removal. A significant reduction in PSA (p = 0.01) and an improvement in IPSS (p = 0.009), IPSS-QoL (p = 0.02) and ICIQ-SF scores (p = 0.04) compared to baseline were observed at the 3-month follow-up. Erectile and ejaculatory functions did not show any significant variation during the follow-up. No intra- and peri-operative complications were recorded. Three Clavien–Dindo post-operative complications were recorded (12%): grade 1 (two cases of urinary retention) and grade 2 (one case of urinary tract infection). At the 12-month follow-up, eight patients showed mpMRI images referable to suspicious recurrent disease (PIRADS v2.1 ≥ 3). After re-biopsy, 7/24 patients’ (29%) results were histologically confirmed as PCa, 3 of which were recurrences in the treated lesion (12.5%). The success rate was 87.5%. Conclusions: The focal TPLA oncological and functional results seemed to be encouraging. TPLA is a safe, painless, and effective technique with a good preservation of continence and sexual outcomes. Recurrence rate at 12 months was about 12.5%.
Open AccessTransperineal Laser Ablation for Focal Therapy of Localized Prostate Cancer: 12-Month Follow-up Outcomes from a Single Prospective Cohort Study
Introduction and objectives: To evaluate the oncological and functional outcomes of transperineal laser ablation (TPLA) as the focal therapy for localized prostate cancer (PCa) after a 12-month follow-up. Materials and methods: Patients with low- and intermediate-risk localized PCa were prospectively treated with focal TPLA between July 2021 and December 2022. The inclusion criteria were the following: clinical stage < T2b; PSA < 20 ng/mL; International Society of Urological Pathology (ISUP) grade ≤ 2; MRI-fusion biopsy-confirmed lesion classified as PI-RADS v2.1 ≥ 3. Intra-, peri-, and post-operative data were collected. Variables including age, PSA, prostate volume (PVol), Charlson’s Comorbidity Index (CCI), International Prostate Symptom Score (IPSS) with QoL score, International Index of Erectile Function (IIEF-5), International Consultation on Incontinence Questionnaire—Short Form (ICIQ-SF), and Male Sexual Health Questionnaire—Ejaculatory Dysfunction Short Form (MSHQ-EjD) were collected at baseline and at 3, 6 and 12 months after TPLA. Post-operative mpMRI was performed at 3 and 12 months. Finally, all patients underwent prostatic re-biopsy under fusion guidance at 12 months. The success of this technique was defined as no recurrence in the target treated lesion at the 12-month follow up. Results: Twenty-four patients underwent focal TPLA. Baseline features were age [median 67 years (IQR 12)], PSA [5.7 ng/mL (3.9)], PVol [49 mL (27)], CCI [0 (0)], IPSS [11 (9)], IPSS-QoL [2 (2)], IIEF-5 [21 (6)], ICIQ-SF [0 (7)], MSHQ-EjD ejaculation domain [14 (4)] and bother score [0 (2)]. Median operative time was 34 min (IQR 12). Median visual analogue scale (VAS) 6 h after TPLA was 0 (IQR 1). The post-operative course was regular for all patients, who were discharged on the second post-operative day and underwent catheter removal on the seventh post-operative day. No patient had incontinence at catheter removal. A significant reduction in PSA (p = 0.01) and an improvement in IPSS (p = 0.009), IPSS-QoL (p = 0.02) and ICIQ-SF scores (p = 0.04) compared to baseline were observed at the 3-month follow-up. Erectile and ejaculatory functions did not show any significant variation during the follow-up. No intra- and peri-operative complications were recorded. Three Clavien–Dindo post-operative complications were recorded (12%): grade 1 (two cases of urinary retention) and grade 2 (one case of urinary tract infection). At the 12-month follow-up, eight patients showed mpMRI images referable to suspicious recurrent disease (PIRADS v2.1 ≥ 3). After re-biopsy, 7/24 patients’ (29%) results were histologically confirmed as PCa, 3 of which were recurrences in the treated lesion (12.5%). The success rate was 87.5%. Conclusions: The focal TPLA oncological and functional results seemed to be encouraging. TPLA is a safe, painless, and effective technique with a good preservation of continence and sexual outcomes. Recurrence rate at 12 months was about 12.5%.
- Open Access
- 22 February 2023
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 95 (1) , 10748
Determinants of renal papillary appearance in kidney stone formers: An in-depth examination
Objectives: The aim of this study is to investi-gate the association between the urinary metabolic milieu and kidney stone recurrence with a validated papillary evaluation score (PPLA). Materials and methods: We prospectively enrolled 30 stone for-mers who underwent retrograde intrarenal surgery procedures. Visual inspection of the accessible renal papillae was performed to calculate PPLA score, based on the characterization of ductal plugging, surface pitting, loss of papillary contour and Randall’s plaque extension. Stone compositions, 24h urine collections and kidney stone events during follow-up were collected. Relative supersaturation ratios (RSS) for calcium oxalate (CaOx), brushite and uric acid were calculated using EQUIL-2. PPLA score > 3 was defined as high. Results: Median follow-up period was 11 months (5, 34). PPLA score was inversely correlated with BMI (OR 0.59, 95% CI 0.38, 0.91, p = 0.018), type 2 diabetes (OR 0.04, 95% CI 0.003, 0.58, p = 0.018) and history of recurrent kidney stones (OR 0.17, 95%CI 0.04, 0.75, p = 0.019). The associations between PPLA score, diabetes and BMI were not confirmed after excluding patients with uric acid stones. Higher PPLA score was associated with lower odds of new kidney stone events during follow-up (OR 0.15, 95% CI 0.02, 1.00, p = 0.05). No other significant correla-tions were found. Conclusions: Our results confirm the lack of efficacy of PPLA score in phenotyping patients affected by kidney stone disease or in predicting the risk of stone recurrence. Larger, long-term studies need to be performed to clarify the role of PPLA on the risk of stone recurrence.
- 22 February 2023
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 95 (1) , 10748
Open AccessDeterminants of renal papillary appearance in kidney stone formers: An in-depth examination
Objectives: The aim of this study is to investi-gate the association between the urinary metabolic milieu and kidney stone recurrence with a validated papillary evaluation score (PPLA). Materials and methods: We prospectively enrolled 30 stone for-mers who underwent retrograde intrarenal surgery procedures. Visual inspection of the accessible renal papillae was performed to calculate PPLA score, based on the characterization of ductal plugging, surface pitting, loss of papillary contour and Randall’s plaque extension. Stone compositions, 24h urine collections and kidney stone events during follow-up were collected. Relative supersaturation ratios (RSS) for calcium oxalate (CaOx), brushite and uric acid were calculated using EQUIL-2. PPLA score > 3 was defined as high. Results: Median follow-up period was 11 months (5, 34). PPLA score was inversely correlated with BMI (OR 0.59, 95% CI 0.38, 0.91, p = 0.018), type 2 diabetes (OR 0.04, 95% CI 0.003, 0.58, p = 0.018) and history of recurrent kidney stones (OR 0.17, 95%CI 0.04, 0.75, p = 0.019). The associations between PPLA score, diabetes and BMI were not confirmed after excluding patients with uric acid stones. Higher PPLA score was associated with lower odds of new kidney stone events during follow-up (OR 0.15, 95% CI 0.02, 1.00, p = 0.05). No other significant correla-tions were found. Conclusions: Our results confirm the lack of efficacy of PPLA score in phenotyping patients affected by kidney stone disease or in predicting the risk of stone recurrence. Larger, long-term studies need to be performed to clarify the role of PPLA on the risk of stone recurrence.
- Open Access
- 27 December 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (1) , 198
Robotic Off-Clamp Simple Enucleation Single-Layer Renorrhaphy Partial Nephrectomy (ROSS): Surgical Insights after an Initial Experience
Robotic technology allows the beginner surgeon to approach minimally-invasive partial nephrectomy (PN) avoiding the otherwise long learning curve of pure laparoscopy. The present video-article reported the surgical technique and the outcomes of the first 11 cases performed by a young surgeon starting with the experience of robotic PN. Transperitoneal robotic PN, with an off-clamp approach, a simple enucleation technique, and a single-layer medullar renorrhaphy was performed uneventfully in all cases but one, with comparable outcomes to the available literature. With the present experience, we are trying to give the reader a different point of view of the current knowledge. In our series, off-clamp robotic PN was not chosen while looking for a better functional outcome, but rather as a “forced” choice within the specific “in training” setting the interventions were performed in. We underline how the off-clamp approach was the way to cut out the potential for vascular complications derived from the application/removal of the clamp itself on the renal artery. Indeed, when Scanlan bulldogs are not available, one of the limits of robotic PN is that the first surgeon is not autonomous in placing/removing the clamp. We found that tumour enucleation resection technique had the perfect synergistic effect in maximizing the perioperative vision, and thus the safety, notwithstanding the clampless approach.
- 27 December 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (1) , 198
Open AccessRobotic Off-Clamp Simple Enucleation Single-Layer Renorrhaphy Partial Nephrectomy (ROSS): Surgical Insights after an Initial Experience
Robotic technology allows the beginner surgeon to approach minimally-invasive partial nephrectomy (PN) avoiding the otherwise long learning curve of pure laparoscopy. The present video-article reported the surgical technique and the outcomes of the first 11 cases performed by a young surgeon starting with the experience of robotic PN. Transperitoneal robotic PN, with an off-clamp approach, a simple enucleation technique, and a single-layer medullar renorrhaphy was performed uneventfully in all cases but one, with comparable outcomes to the available literature. With the present experience, we are trying to give the reader a different point of view of the current knowledge. In our series, off-clamp robotic PN was not chosen while looking for a better functional outcome, but rather as a “forced” choice within the specific “in training” setting the interventions were performed in. We underline how the off-clamp approach was the way to cut out the potential for vascular complications derived from the application/removal of the clamp itself on the renal artery. Indeed, when Scanlan bulldogs are not available, one of the limits of robotic PN is that the first surgeon is not autonomous in placing/removing the clamp. We found that tumour enucleation resection technique had the perfect synergistic effect in maximizing the perioperative vision, and thus the safety, notwithstanding the clampless approach.
- Open Access
Calcium and Vitamin D Supplementation and Their Association with Kidney Stone Disease: A Narrative Review
Kidney stone disease is a multifactorial condition influenced by both genetic predisposition and environmental factors such as lifestyle and dietary habits. Although different monogenic polymorphisms have been proposed as playing a causal role for calcium nephrolithiasis, the prevalence of these mutations in the general population and their complete pathogenetic pathway is yet to be determined. General dietary advice for kidney stone formers includes elevated fluid intake, dietary restriction of sodium and animal proteins, avoidance of a low calcium diet, maintenance of a normal body mass index, and elevated intake of vegetables and fibers. Thus, balanced calcium consumption protects against the risk for kidney stones by reducing intestinal oxalate availability and its urinary excretion. However, calcium supplementation given between meals might increase urinary calcium excretion without the beneficial effect on oxalate. In kidney stone formers, circulating active vitamin D has been found to be increased, whereas higher plasma 25-hydroxycholecalciferol seems to be present only in hypercalciuric patients. The association between nutritional vitamin D supplements and the risk for stone formation is currently not completely understood. However, taken together, available evidence might suggest that vitamin D administration worsens the risk for stone formation in patients predisposed to hypercalciuria. In this review, we analyzed and discussed available literature on the effect of calcium and vitamin D supplementation on the risk for kidney stone formation.
Open AccessCalcium and Vitamin D Supplementation and Their Association with Kidney Stone Disease: A Narrative Review
Kidney stone disease is a multifactorial condition influenced by both genetic predisposition and environmental factors such as lifestyle and dietary habits. Although different monogenic polymorphisms have been proposed as playing a causal role for calcium nephrolithiasis, the prevalence of these mutations in the general population and their complete pathogenetic pathway is yet to be determined. General dietary advice for kidney stone formers includes elevated fluid intake, dietary restriction of sodium and animal proteins, avoidance of a low calcium diet, maintenance of a normal body mass index, and elevated intake of vegetables and fibers. Thus, balanced calcium consumption protects against the risk for kidney stones by reducing intestinal oxalate availability and its urinary excretion. However, calcium supplementation given between meals might increase urinary calcium excretion without the beneficial effect on oxalate. In kidney stone formers, circulating active vitamin D has been found to be increased, whereas higher plasma 25-hydroxycholecalciferol seems to be present only in hypercalciuric patients. The association between nutritional vitamin D supplements and the risk for stone formation is currently not completely understood. However, taken together, available evidence might suggest that vitamin D administration worsens the risk for stone formation in patients predisposed to hypercalciuria. In this review, we analyzed and discussed available literature on the effect of calcium and vitamin D supplementation on the risk for kidney stone formation.